USPTO To Reexamine Lipitor Patent

Law360, New York (December 8, 2004, 12:00 AM EST) -- In a troubling development for Pfizer Inc., the U.S. Patent and Trademark Office has agreed to reexamine the drug maker’s patent on the cholesterol-lowering treatment Lipitor, the world’s best-selling drug.

The USPTO issued its order based on a request by a small activist group, the Public Patent Foundation (PUBPAT), stating that the request raised "a substantial new question of patentability" regarding all 44 claims of the patent.

PUBPAT claims that the patent in question, issued in 1999 for a crystalline form of the drug, should be...
To view the full article, register now.